Cargando…

A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort

PURPOSE: To provide more insight into late treatment-related toxicities among breast cancer (BC) survivors by comparing morbidities and risk factors between BC survivors and age-matched controls. MATERIALS AND METHODS: All female participants diagnosed with BC before inclusion in Lifelines, a popula...

Descripción completa

Detalles Bibliográficos
Autores principales: Spoor, D.S., van den Bogaard, V.A.B., Sijtsema, N.M., Van der Meer, P., de Bock, G.H., Langendijk, J.A., Maduro, J.H., Crijns, A.P.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293765/
https://www.ncbi.nlm.nih.gov/pubmed/37331094
http://dx.doi.org/10.1016/j.breast.2023.06.002
_version_ 1785063060695678976
author Spoor, D.S.
van den Bogaard, V.A.B.
Sijtsema, N.M.
Van der Meer, P.
de Bock, G.H.
Langendijk, J.A.
Maduro, J.H.
Crijns, A.P.G.
author_facet Spoor, D.S.
van den Bogaard, V.A.B.
Sijtsema, N.M.
Van der Meer, P.
de Bock, G.H.
Langendijk, J.A.
Maduro, J.H.
Crijns, A.P.G.
author_sort Spoor, D.S.
collection PubMed
description PURPOSE: To provide more insight into late treatment-related toxicities among breast cancer (BC) survivors by comparing morbidities and risk factors between BC survivors and age-matched controls. MATERIALS AND METHODS: All female participants diagnosed with BC before inclusion in Lifelines, a population-based cohort in the Netherlands, were selected and matched 1:4 to female controls without any oncological history on birth year. Baseline was defined as the age at BC diagnosis. Outcomes were obtained from questionnaires and functional analyses performed at entry to Lifelines (follow-up 1; FU1) and several years later (FU2). Cardiovascular and pulmonary events were defined as morbidities that were absent at baseline but present at FU1 or FU2. RESULTS: The study consisted of 1,325 BC survivors and 5,300 controls. The median period from baseline (i.e., BC treatment) to FU1 and FU2 was 7 and 10 years, respectively. Among BC survivors more events of heart failure (OR: 1.72 [1.10–2.68]) and less events of hypertension (OR: 0.79 [0.66–0.94]) were observed. At FU2, more electrocardiographic abnormalities were found among BC survivors compared to controls (4.1% vs. 2.7%, respectively; p = 0.027) and Framingham scores for the 10-year risk of coronary heart disease were lower (difference: 0.37%; 95% CI [-0.70 to -0.03%]). At FU2, BC survivors had more frequently a forced vital capacity below the lower limit of normal than controls (5.4% vs. 2.9%, respectively; p = 0.040). CONCLUSION: BC survivors are at risk of late treatment-related toxicities despite a more favourable cardiovascular risk profile compared to age-matched female controls.
format Online
Article
Text
id pubmed-10293765
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102937652023-06-28 A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort Spoor, D.S. van den Bogaard, V.A.B. Sijtsema, N.M. Van der Meer, P. de Bock, G.H. Langendijk, J.A. Maduro, J.H. Crijns, A.P.G. Breast Original Article PURPOSE: To provide more insight into late treatment-related toxicities among breast cancer (BC) survivors by comparing morbidities and risk factors between BC survivors and age-matched controls. MATERIALS AND METHODS: All female participants diagnosed with BC before inclusion in Lifelines, a population-based cohort in the Netherlands, were selected and matched 1:4 to female controls without any oncological history on birth year. Baseline was defined as the age at BC diagnosis. Outcomes were obtained from questionnaires and functional analyses performed at entry to Lifelines (follow-up 1; FU1) and several years later (FU2). Cardiovascular and pulmonary events were defined as morbidities that were absent at baseline but present at FU1 or FU2. RESULTS: The study consisted of 1,325 BC survivors and 5,300 controls. The median period from baseline (i.e., BC treatment) to FU1 and FU2 was 7 and 10 years, respectively. Among BC survivors more events of heart failure (OR: 1.72 [1.10–2.68]) and less events of hypertension (OR: 0.79 [0.66–0.94]) were observed. At FU2, more electrocardiographic abnormalities were found among BC survivors compared to controls (4.1% vs. 2.7%, respectively; p = 0.027) and Framingham scores for the 10-year risk of coronary heart disease were lower (difference: 0.37%; 95% CI [-0.70 to -0.03%]). At FU2, BC survivors had more frequently a forced vital capacity below the lower limit of normal than controls (5.4% vs. 2.9%, respectively; p = 0.040). CONCLUSION: BC survivors are at risk of late treatment-related toxicities despite a more favourable cardiovascular risk profile compared to age-matched female controls. Elsevier 2023-06-08 /pmc/articles/PMC10293765/ /pubmed/37331094 http://dx.doi.org/10.1016/j.breast.2023.06.002 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Spoor, D.S.
van den Bogaard, V.A.B.
Sijtsema, N.M.
Van der Meer, P.
de Bock, G.H.
Langendijk, J.A.
Maduro, J.H.
Crijns, A.P.G.
A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort
title A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort
title_full A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort
title_fullStr A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort
title_full_unstemmed A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort
title_short A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort
title_sort comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the lifelines prospective population cohort
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293765/
https://www.ncbi.nlm.nih.gov/pubmed/37331094
http://dx.doi.org/10.1016/j.breast.2023.06.002
work_keys_str_mv AT spoords acomparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT vandenbogaardvab acomparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT sijtsemanm acomparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT vandermeerp acomparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT debockgh acomparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT langendijkja acomparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT madurojh acomparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT crijnsapg acomparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT spoords comparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT vandenbogaardvab comparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT sijtsemanm comparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT vandermeerp comparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT debockgh comparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT langendijkja comparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT madurojh comparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort
AT crijnsapg comparisonofcardiovascularandpulmonarymorbiditiesandriskfactorsinbreastcancersurvivorscomparedtoanagematchedfemalecontrolgroupinthelifelinesprospectivepopulationcohort